If you have been reading about prohibited substance and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-06-16. Numbers and descriptions here follow the published literature rather than marketing material.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
| Property | Value | Notes |
|---|---|---|
| Reconstitution solvent | Sterile water or aqueous buffer | Aseptic technique recommended |
| Post-reconstitution storage | 2–8 °C short term; frozen for longer periods | Avoid repeated freeze-thaw cycles |
| Typical purity assay | Reversed-phase HPLC | Peak area used to estimate purity |
| Identity confirmation | Mass measurement | Compares observed value with expected mass |
| Main degradation routes | Hydrolysis and oxidation | Accelerated by heat and extreme pH |
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
To predict if the production of mendelevium would be possible, the team made use of a rough calculation. The number of atoms that would be produced would be approximately equal to the product of the number of atoms of target material, the target's cross section, the ion beam intensity, and the time of bombardment; this last factor was related to the half-life of the product when bombarding for a time on the order of its half-life. This gave one atom per experiment. Thus under optimum conditions, the preparation of only one atom of element 101 per experiment could be expected. This calculation demonstrated that it was feasible to go ahead with the experiment. The target material, 253Es, could be produced readily from irradiating plutonium: one year of irradiation would give a billion atoms, and its three-week half-life meant that the element 101 experiments could be conducted in one week after the produced einsteinium was separated and purified to make the target. However, it was necessary to upgrade the cyclotron to obtain the needed intensity of 1014 alpha particles per second; Seaborg applied for the necessary funds.
External factors may limit the ability of an enzyme to catalyse a reaction in both directions (whereas the nature of a catalyst in itself means that it cannot catalyse just one direction, according to the principle of microscopic reversibility). We consider the case of an enzyme that catalyses the reaction in both directions:
Many other physical properties of the elements exhibit periodic variation in accordance with the periodic law, such as melting points, boiling points, heats of fusion, heats of vaporization, atomisation energy, and so on. Similar periodic variations appear for the compounds of the elements, which can be observed by comparing hydrides, oxides, sulfides, halides, and so on. Chemical properties are more difficult to describe quantitatively, but likewise exhibit their own periodicities. Examples include the variation in the acidic and basic properties of the elements and their compounds, the stabilities of compounds, and methods of isolating the elements. Periodicity is and has been used very widely to predict the properties of unknown new elements and new compounds, and is central to modern chemistry.
Sources: en.wikipedia.org
Mass spectrometry is used to separate and measure distinct isotopes present in a sample. Archaeologists typically employ isotope ratio mass spectrometers or IRMSs, consisting of an inlet system, ion source, mass analyser and multiple ion detectors. The sample is usually introduced into the mass spectrometer as a gas, with oxygen and carbon being introduced as carbon dioxide. Strontium is too unstable to be easily handled in gas form, instead, it is evaporated and ionised in a vacuum. This use of a solid source is referred to as thermal ionisation mass spectrometry or TIMS. More recently, strontium isotopes have been at the centre of discussion and investigation into the use of laser ablation inductively coupled mass spectrometry (ICP-MS), which is also of interest due to its less invasive nature. Electron bombardment ionises the gas, allowing the molecules to be focused into a beam which is then split by mass into smaller beams - forming a "mass spectrum". The relative intensities of the different beams is then measured in the ion collector and relayed as isotope ratios.
== Research == In addition to muscle spasticity, tizanidine was under development for the treatment of fibromyalgia and migraine, but development for these indications was discontinued. Several other formulations have also been developed for various indications, including spastic paralysis, musculoskeletal pain, and back pain, but likewise have not been marketed. An intranasal formulation was in phase 3 clinical trials for back pain as of 2017.
=== Pediatrics === In pediatrics, a 2023 time-series study published in JAMA Pediatrics examined first-time pediatric speech delay incidence from 2018 to 2022 using data from U.S. health systems, including those affiliated with Truveta. A 2025 study in Pediatrics Open Science examined changes in pediatric obesity treatment practices in the United States following updated guidelines from the American Academy of Pediatrics, using data from large health-system records, including those affiliated with Truveta.
== E == EEG (Electroencephalography) A non-invasive method of recording electrical activity in the brain using electrodes placed on the scalp. It is commonly used to study sleep, epilepsy, and cognitive processes. Effector A muscle, gland, or organ that performs an action in response to a neural signal, typically from the motor neuron. Efferent nerve fiber An axon that carries motor signals away from the central nervous system to muscles or glands. Opposite of afferent nerve fiber. Electroconvulsive therapy (ECT) A psychiatric treatment in which seizures are electrically induced in anesthetized patients for therapeutic effect, often used for treatment-resistant depression. Electrode A conductor used to detect or deliver electrical signals in neural recording or stimulation. Electrodes can be surface (non-invasive), intracranial, or implanted. Electromyography (EMG) A technique for recording the electrical activity produced by skeletal muscles, often used in neuromuscular diagnostics and motor control studies. Electrophysiology The study of the electrical properties of biological cells and tissues. In neuroscience, it often involves measuring voltage changes or currents in neurons. Endocannabinoid system A neuromodulatory system composed of endocannabinoids, receptors (e.g., CB1), and enzymes. It regulates processes such as appetite, pain, mood, and memory. Endocrine system A collection of glands that secrete hormones directly into the bloodstream. It interacts with the nervous system to regulate metabolism, stress, and growth.
Sources: en.wikipedia.org
In 1984, Applied Biosystems sales revenue tripled to over US$18 million, with a second yearly profit, and with over 200 employees. Services included synthesizing custom DNA and protein fragments, and the sequencing of protein samples submitted from customers. The third major instrument made by Applied, the Model 430A Peptide Synthesizer, was introduced. In 1985, Applied Biosystems sales revenue grew nearly 70% to over US$35 million, with a third yearly profit. Two new products included the Model 380B DNA Synthesizer and the 381A DNA Synthesizer. That year the company went international for the first time, when it established a wholly owned subsidiary in Great Britain to save shipping costs on chemical sales, which overall by then accounted for 17% of sales. Also in 1985, Applied Biosystems acquired Brownlee Labs, a manufacturer of columns and pumps for high-performance liquid chromatography (HPLC) systems, after its founder, Robert Brownlee was diagnosed with AIDS-related complex in 1984. Brownlee's technology brought the new on-line 120A PTH Amino Acid Analyzer. However, Brownlee then began a new company, which was viewed by Applied as a competitor. In 1989 Applied and Brownlee settled in a lawsuit over the conflict. As late as 1990, Brownlee publicly discussed what had been his contributions in the rocky relationship with Applied, before he died early the next year. In 1986, Andre Marion became president and chief executive officer. Sales revenue increased by 45% to nearly US$52 million. The company introduced six new products, totalling eleven automated instruments.
Bachem Holding AG is a Swiss biotechnology company specializing in the development and manufacture of peptides and complex organic molecules for use as active pharmaceutical ingredients (APIs). The company focuses on peptide-based therapeutics, including large-scale commercial production and process development for pharmaceutical applications. It was founded in 1971 and is a subsidiary of Ingro Finanz AG. The head office is in Bubendorf in the canton of Basel-Landschaft. Bachem operates production facilities in Vionnaz (Switzerland), Vista and Torrance (United States), and St Helens (United Kingdom), as well as a sales and distribution site in Tokyo. Bachem is one of the largest manufacturers of peptide-based APIs globally, supplying pharmaceutical and biotechnology companies with products used in both clinical development and commercial therapies. In recent years, the company has expanded its manufacturing capacity, including new large-scale production facilities in Switzerland and the United States. At the end of 2025, the company employed 2,511 people, reported revenue of CHF 695.1 million, and net income of CHF 148.8 million.
Kruja, headquartered at the tekke of Fushë-Krujë Elbasan, headquartered at the tekke of Krastë, Dibër Korça, headquartered at the tekke of Melçan Gjirokastra, headquartered at the tekke of Asim Baba Prishta, representing Berat and part of Përmet Vlora, headquartered at the tekke of Frashër National headquarters in other countries are located in:
Sources: en.wikipedia.org
Standard practice is a desiccated container at −20 °C, protected from light and kept sealed between uses. Letting the vial reach room temperature before opening reduces condensation on the powder. Repeated warming and cooling of the whole container is generally avoided.
There is no broadly accepted figure for TB-500. Laboratory practice is short-term storage at 2–8 °C with longer-term aliquots frozen, and degradation is expected to increase with time and temperature. Users typically rely on their own stability checks rather than published data.
Mass measurement provides the clearest confirmation by matching an observed value to the expected one. Reversed-phase chromatography adds a purity estimate through peak integration. Combining both is standard because neither alone establishes identity and purity together.
Sealed, desiccated and protected from light, at -20 °C or lower for long-term storage. Short-term storage at refrigerator temperature is common in working laboratories.